Premium
Norplant® use by women with sickle cell disease
Author(s) -
Ladipo O.A.,
Falusi A.G.,
Feldblum P.J.,
Osotimehin B.O.,
Otolorin E.O.,
Ojengbede O.A.
Publication year - 1993
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(93)90159-t
Subject(s) - medicine , levonorgestrel , creatinine , aspartate transaminase , albumin , population , anemia , sickle cell anemia , disease , family planning , physiology , gynecology , alkaline phosphatase , research methodology , biochemistry , chemistry , environmental health , enzyme
OBJECTIVE: To assess the safety of Norplant® contraceptive implant use by women with mild‐moderate homozygous sickle cell disease (HbSS). METHOD: Prospective observation of women pre‐ and post‐insertion of Norplant®, with each woman serving as her own control. Participants: 25 women 18–40 years of age who attended a hospital sickle cell clinic; post‐insertion data were available for 23 women. Outcome measures: Changes in hematologic parameters including PCV, MCV, reticulocytes, ISCs, HbF and bilirubin; changes in biochemical parameters including HDL cholesterol, aspartate transaminase, alkaline phosphate, serum creatinine and serum albumin. RESULT: With a mean follow‐up of 12.4 months (range 1–29 months), there were no clinically or statistically significant group or individual changes in the hematologic or biochemical parameters after Norplant® insertion. CONCLUSION: Norplant® appears to be a safe and appropriate contraceptive for women with mild‐moderate HbSS disease.